BACKGROUND: Severe liver steatosis is a known risk factor for increased ischemia-reperfusion injury (IRI) and poor outcomes after liver transplantation (LT). This study aimed to identify steatosis-related molecular mechanisms associated with IRI exacerbation after LT. METHODS: Paired graft biopsies (n = 60) were collected before implantation (L1) and 90 minutes after reperfusion (L2). The LT recipients (n = 30) were classified by graft macrosteatosis: without steatosis (WS) of 5% or less (n = 13) and with steatosis (S) of 25% or greater (n = 17). Plasma samples were collected at L1, L2, and 1 day after LT (postoperative [POD]1) for cytokines evaluation. Tissue RNA was isolated for gene expression microarrays. Probeset summaries were obtained using robust multiarray average algorithm. Pairwise comparisons were fit using 2-sample t test. P values 0.01 or less were significant (false discovery rate <5%). Molecular pathway analyses were conducted using Ingenuity Pathway Analysis tool. RESULTS: Significantly differentially expressed genes were identified for WS and S grafts after reperfusion. Comprehensive comparison analysis of molecular profiles revealed significant association of S grafts molecular profile with innate immune response activation, macrophage production of nitric oxide and reactive oxygen species, IL-6, IL-8, IL-10 signaling activation, recruitment of granulocytes, and accumulation of myeloid cells. Postreperfusion histological patterns of S grafts revealed neutrophilic infiltration surrounding fat accumulation. Circulating proinflammatory cytokines after reperfusion and 24 hours after LT concurred with intragraft-deregulated molecular pathways. All tested cytokines were significantly increased in plasma of S grafts recipients after reperfusion when compared with WS group at same time. CONCLUSIONS: Increases of graft steatosis exacerbate IRI by exacerbation of innate immune response after LT. Preemptive strategies should consider it for safety usage of steatotic livers.
BACKGROUND: Severe liver steatosis is a known risk factor for increased ischemia-reperfusion injury (IRI) and poor outcomes after liver transplantation (LT). This study aimed to identify steatosis-related molecular mechanisms associated with IRI exacerbation after LT. METHODS: Paired graft biopsies (n = 60) were collected before implantation (L1) and 90 minutes after reperfusion (L2). The LT recipients (n = 30) were classified by graft macrosteatosis: without steatosis (WS) of 5% or less (n = 13) and with steatosis (S) of 25% or greater (n = 17). Plasma samples were collected at L1, L2, and 1 day after LT (postoperative [POD]1) for cytokines evaluation. Tissue RNA was isolated for gene expression microarrays. Probeset summaries were obtained using robust multiarray average algorithm. Pairwise comparisons were fit using 2-sample t test. P values 0.01 or less were significant (false discovery rate <5%). Molecular pathway analyses were conducted using Ingenuity Pathway Analysis tool. RESULTS: Significantly differentially expressed genes were identified for WS and S grafts after reperfusion. Comprehensive comparison analysis of molecular profiles revealed significant association of S grafts molecular profile with innate immune response activation, macrophage production of nitric oxide and reactive oxygen species, IL-6, IL-8, IL-10 signaling activation, recruitment of granulocytes, and accumulation of myeloid cells. Postreperfusion histological patterns of S grafts revealed neutrophilic infiltration surrounding fat accumulation. Circulating proinflammatory cytokines after reperfusion and 24 hours after LT concurred with intragraft-deregulated molecular pathways. All tested cytokines were significantly increased in plasma of S grafts recipients after reperfusion when compared with WS group at same time. CONCLUSIONS: Increases of graft steatosis exacerbate IRI by exacerbation of innate immune response after LT. Preemptive strategies should consider it for safety usage of steatotic livers.
Authors: Jan P Deroose; Geert Kazemier; Pieter Zondervan; Jan N M Ijzermans; Herold J Metselaar; Ian P J Alwayn Journal: HPB (Oxford) Date: 2011-04-07 Impact factor: 3.647
Authors: Austin L Spitzer; Oliver B Lao; André A S Dick; Ramasamy Bakthavatsalam; Jeffrey B Halldorson; Matthew M Yeh; Melissa P Upton; Jorge D Reyes; James D Perkins Journal: Liver Transpl Date: 2010-07 Impact factor: 5.799
Authors: Elizabeth S Gold; Alan H Diercks; Irina Podolsky; Rebecca L Podyminogin; Peter S Askovich; Piper M Treuting; Alan Aderem Journal: Proc Natl Acad Sci U S A Date: 2014-07-03 Impact factor: 11.205
Authors: Justin D Ellett; Zachary P Evans; Carl Atkinson; Michael G Schmidt; Rick G Schnellmann; Kenneth D Chavin Journal: Liver Transpl Date: 2009-09 Impact factor: 5.799
Authors: D Degli Esposti; M Sebagh; P Pham; M Reffas; C Poüs; C Brenner; D Azoulay; A Lemoine Journal: Cell Death Dis Date: 2011-01-13 Impact factor: 8.469
Authors: Jan M Knaak; Vinzent N Spetzler; Nicolas Goldaracena; Kristine S Louis; Nazia Selzner; Markus Selzner Journal: J Vis Exp Date: 2014-08-13 Impact factor: 1.355
Authors: J M Diamond; E Cantu; M K Porteous; Y Suzuki; K C Meyer; D J Lederer; R K Milewski; S Arcasoy; F D'Ovidio; M Bacchetta; J R Sonett; G Singh; J Costa; J W Tobias; H Rodriguez; V M Van Deerlin; K M Olthoff; A Shaked; B-L Chang; J D Christie Journal: Am J Transplant Date: 2017-02-17 Impact factor: 8.086
Authors: Esteban Fuentes-Valenzuela; Javier Tejedor-Tejada; Félix García-Pajares; Beatriz M Rubiales; Rodrigo Nájera-Muñoz; Carlos Maroto-Martín; Laura Sánchez-Delgado; Carmen Alonso-Martín; Carolina A Álvarez; Gloria Sánchez-Antolín Journal: J Clin Exp Hepatol Date: 2022-01-04